PE20171110A1 - Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y usos de los mismos - Google Patents
Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y usos de los mismosInfo
- Publication number
- PE20171110A1 PE20171110A1 PE2017000467A PE2017000467A PE20171110A1 PE 20171110 A1 PE20171110 A1 PE 20171110A1 PE 2017000467 A PE2017000467 A PE 2017000467A PE 2017000467 A PE2017000467 A PE 2017000467A PE 20171110 A1 PE20171110 A1 PE 20171110A1
- Authority
- PE
- Peru
- Prior art keywords
- methyl
- dihydropyridin
- oxo
- halogen
- alkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Se refiere a un derivado de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo de formula I o una sal del mismo farmaceuticamente aceptable, donde R1 es halogeno, metilo o halometilo; R2 es halogeno; R3A, R3B y R3C son H, halogeno, halometilo o halometoxi; R4 es H, halogeno y metilo; R5 es metilo o etilo. Entre los compuestos preferidos tenemos: 2,2-difluoro-N-[(1R,2S)-3-metil-1-{[1-(1-metil-6-oxo-1,6-dihidropiridin-3-il)-1H-indazol-5-il]oxi}-1-fenilbutan-2-il]propanamida; 2,2,2-trifluoro-N-[(1R,2S)-3-metil-1-{[1-(1-metil-6-oxo-1,6-dihidropiridin-3-il)-1H-indazol-5-il]oxi}-1-fenilbutan-2-il]acetamida; entre otros. Tambien esta referida a una composicion farmaceutica. Dichos compuestos actuan sobre los receptores de glucocorticoides siendo utiles en el tratamiento de artritis reumatoidea, asma, entre otros
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462055822P | 2014-09-26 | 2014-09-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20171110A1 true PE20171110A1 (es) | 2017-08-07 |
Family
ID=54252264
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2017000467A PE20171110A1 (es) | 2014-09-26 | 2015-09-23 | Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y usos de los mismos |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US10196374B2 (es) |
| EP (1) | EP3197878B1 (es) |
| JP (1) | JP6430000B2 (es) |
| KR (1) | KR101866706B1 (es) |
| CN (1) | CN107001320B (es) |
| AP (1) | AP2017009819A0 (es) |
| AR (1) | AR105549A1 (es) |
| AU (1) | AU2015323817B2 (es) |
| BR (1) | BR112017006085B1 (es) |
| CA (1) | CA2962312C (es) |
| CL (1) | CL2017000715A1 (es) |
| CO (1) | CO2017003955A2 (es) |
| CR (1) | CR20170106A (es) |
| DO (1) | DOP2017000064A (es) |
| EA (1) | EA031945B1 (es) |
| ES (1) | ES2751640T3 (es) |
| GT (1) | GT201700058A (es) |
| IL (1) | IL250886A0 (es) |
| MX (1) | MX2017003697A (es) |
| NI (1) | NI201700038A (es) |
| NZ (1) | NZ730250A (es) |
| PE (1) | PE20171110A1 (es) |
| PH (1) | PH12017500533A1 (es) |
| SG (1) | SG11201702225VA (es) |
| SV (1) | SV2017005412A (es) |
| TN (1) | TN2017000096A1 (es) |
| TW (1) | TW201619146A (es) |
| UY (1) | UY36327A (es) |
| WO (1) | WO2016046260A1 (es) |
| ZA (1) | ZA201702720B (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017161518A1 (en) * | 2016-03-23 | 2017-09-28 | Astrazeneca Ab | New physical form |
| TW201927769A (zh) | 2017-12-18 | 2019-07-16 | 德商歌林達有限公司 | 經取代之吡咯啶醯胺ｉｉ |
| AR113967A1 (es) | 2017-12-18 | 2020-07-01 | Gruenenthal Gmbh | Pirrolidinamidas i sustituidas |
| WO2020144375A1 (en) | 2019-01-11 | 2020-07-16 | Grünenthal GmbH | Substituted pyrrolidine amides iii |
| WO2020254551A1 (en) | 2019-06-19 | 2020-12-24 | Grünenthal GmbH | Substituted pyrrolidine amides iv |
| WO2020254552A2 (en) | 2019-06-19 | 2020-12-24 | Grünenthal GmbH | Substituted pyrrolidine amides v |
| US20230167068A1 (en) * | 2019-12-31 | 2023-06-01 | Medshine Discovery Inc. | Benzopyrazole compound |
| WO2022008705A1 (en) | 2020-07-09 | 2022-01-13 | Grünenthal GmbH | Substituted pyrrolidine amines and amides as mediator of the glucocortoid receptor |
| CN115667237A (zh) * | 2020-07-17 | 2023-01-31 | 成都苑东生物制药股份有限公司 | 作为bet抑制剂的新型杂环化合物 |
| WO2023041695A1 (en) | 2021-09-20 | 2023-03-23 | Astrazeneca Ab | Methods of treating inflammatory diseases with a selective glucocorticoid receptor modulator |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2007000615A (es) * | 2004-07-16 | 2007-03-07 | Janssen Pharmaceutica Nv | Compuestos dimericos de piperidina, piperazina o morfolina o sus analogos de 7 miembros adecuados para el tratamiento de trastornos neurodegenerativos. |
| JO2754B1 (en) * | 2006-12-21 | 2014-03-15 | استرازينكا ايه بي | Amylendazoleil derivatives for the treatment of glucocorticoid-mediated disorders |
| UY31831A (es) | 2008-05-20 | 2010-01-05 | Astrazeneca Ab | Derivados de indazoles sustituidos con fenilo o piridinilo |
-
2015
- 2015-09-23 ES ES15775130T patent/ES2751640T3/es active Active
- 2015-09-23 NZ NZ730250A patent/NZ730250A/en not_active IP Right Cessation
- 2015-09-23 CR CR20170106A patent/CR20170106A/es unknown
- 2015-09-23 WO PCT/EP2015/071862 patent/WO2016046260A1/en active Application Filing
- 2015-09-23 PE PE2017000467A patent/PE20171110A1/es unknown
- 2015-09-23 AU AU2015323817A patent/AU2015323817B2/en active Active
- 2015-09-23 TN TN2017000096A patent/TN2017000096A1/en unknown
- 2015-09-23 MX MX2017003697A patent/MX2017003697A/es active IP Right Grant
- 2015-09-23 EP EP15775130.6A patent/EP3197878B1/en active Active
- 2015-09-23 CN CN201580064182.1A patent/CN107001320B/zh active Active
- 2015-09-23 BR BR112017006085-0A patent/BR112017006085B1/pt active IP Right Grant
- 2015-09-23 AP AP2017009819A patent/AP2017009819A0/en unknown
- 2015-09-23 KR KR1020177007804A patent/KR101866706B1/ko active IP Right Grant
- 2015-09-23 EA EA201790496A patent/EA031945B1/ru not_active IP Right Cessation
- 2015-09-23 US US15/513,655 patent/US10196374B2/en active Active
- 2015-09-23 JP JP2017515945A patent/JP6430000B2/ja active Active
- 2015-09-23 SG SG11201702225VA patent/SG11201702225VA/en unknown
- 2015-09-23 CA CA2962312A patent/CA2962312C/en active Active
- 2015-09-25 AR ARP150103099A patent/AR105549A1/es unknown
- 2015-09-25 TW TW104131819A patent/TW201619146A/zh unknown
- 2015-09-25 UY UY0001036327A patent/UY36327A/es not_active Application Discontinuation
-
2017
- 2017-03-02 IL IL250886A patent/IL250886A0/en active IP Right Grant
- 2017-03-08 DO DO2017000064A patent/DOP2017000064A/es unknown
- 2017-03-22 GT GT201700058A patent/GT201700058A/es unknown
- 2017-03-23 PH PH12017500533A patent/PH12017500533A1/en unknown
- 2017-03-24 CL CL2017000715A patent/CL2017000715A1/es unknown
- 2017-03-24 NI NI201700038A patent/NI201700038A/es unknown
- 2017-03-24 SV SV2017005412A patent/SV2017005412A/es unknown
- 2017-04-18 ZA ZA2017/02720A patent/ZA201702720B/en unknown
- 2017-04-24 CO CONC2017/0003955A patent/CO2017003955A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20171110A1 (es) | Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y usos de los mismos | |
| GT201600233A (es) | Compuestos y composiciones como agonistas del receptor tipo toll 7 | |
| CL2018001230A1 (es) | Tratamiento de osteoartritis | |
| CL2017000902A1 (es) | Dihidropirrolopiridinas inhibidoras de ror-gamma | |
| CL2017000240A1 (es) | Compuestos activos hacia bromodominios | |
| CL2016002573A1 (es) | Compuesto de ciclopropanamina y sus usos. | |
| UY36308A (es) | Inhibidores de histona acetiltransferasas espirocíclicas (hat) y métodos para su uso | |
| UY36056A (es) | “compuestos de heteroarilo o arilo bicíclicos fusionados “. | |
| CL2016002072A1 (es) | 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer | |
| CL2017000270A1 (es) | Derivados de heterociclilo opcionalmente condensados de pirimidina útiles para el tratamiento de enfermedades inflamatorias, metabólicas, oncológicas y autoinmunitarias. | |
| CL2016002091A1 (es) | Compuesto de triazina y su uso para fines medicinales | |
| CL2016003329A1 (es) | Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble | |
| CL2016000436A1 (es) | Método para el tratamiento de la enfermedad fibrótica | |
| CU20160140A7 (es) | CROMENE Y 1,1 A,2,7B- tetrahidrociclopropa[C]CROMENE PIRIDOPIRAZINEDIONES COMO MODULADORES DE GAMMA-SECRETASA | |
| UY36166A (es) | Formas de sales de n—(cianometil)—4—(2—(4—morfolinofenilamino)pirimidin—4—il)benzamida, sus composiciones y su uso terapeutico | |
| CL2017000716A1 (es) | Moduladores de pirrolopiridina de rorc2 sustituidos con metilo y trifluorometilo y métodos de uso de los mismos | |
| DOP2017000107A (es) | Diamino-quinoleina 2,4 sustituida como nuevos agentes anticancerigenos | |
| ECSP18003372A (es) | Compuestos tricíclicos y su uso como inhibidores de la fosfodiesterasa | |
| CL2016000597A1 (es) | Derivados de desoxino jirimicina y sus métodos de uso. | |
| DOP2016000297A (es) | Composiciones farmacéuticas útiles para tratar enfermedades infecciosas | |
| AR096338A1 (es) | (ciano-dimetil-metil)-isoxazoles y -[1,3,4]tiadiazoles | |
| UY36190A (es) | Formulación compuesta para la administración oral que comprende ezetimiba y rosuvastatina, y un proceso para su preparación | |
| CR20160527A (es) | Derivados de carboxamida | |
| CL2016002267A1 (es) | Ureas asimétricas p-sustituidas y usos médicos de las mismas | |
| CL2012003539A1 (es) | Compuestos derivados de alquil-piperazino-fenil 4(3h)ona; composicion farmaceutica y su uso para el tratamiento de los trastornos asociados a los receptores serotoninergicos 5-ht1a y 5-ht2a, tales como depresion, ansiedad, y trastornos del sueño. |